

Yu-Wei Chen

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1431445/yu-wei-chen-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37
papers

484
citations

13
h-index

21
g-index

37
ext. papers

603
ext. citations

3.1
avg, IF

3.36
L-index

#	Paper	IF	Citations
37	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015 , 194, 343-9	2.5	88
36	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 683-90	4	41
35	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016 , 118, 95-101	5.6	36
34	Prostate Brachytherapy Case Volumes by Academic and Nonacademic Practices: Implications for Future Residency Training. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 624-8	4	35
33	Association Between Travel Distance and Choice of Treatment for Prostate Cancer: Does Geography Reduce Patient Choice?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 96, 313-317	4	32
32	The decreased use of brachytherapy boost for intermediate and high-risk prostate cancer despite evidence supporting its effectiveness. <i>Brachytherapy</i> , 2016 , 15, 701-706	2.4	27
31	National Trends in Admission for Aspiration Pneumonia in the United States, 2002-2012. <i>Annals of the American Thoracic Society</i> , 2017 , 14, 874-879	4.7	20
30	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016 , 117, E20-8.6	3.6	19
29	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016 , 122, 1505-12	6.4	19
28	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016 , 122, 3371-3377	6.4	17
27	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 57.e15-22	2.8	14
26	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with 50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016 , 87, 125-32	1.6	14
25	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018 , 124, 1146-1149	6.1	14
24	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 525-30.e1-3	3.3	13
23	Cost-effectiveness of Management Options for Small Renal Mass: A Systematic Review. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016 , 39, 484-90	2.7	13
22	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016 , 2, 532-539	5.1	13
21	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 330.e19-25	2.8	12

20	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016 , 15, 695-700	2.4	10
19	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 421-8	7.3	9
18	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018 , 131, 517-523	2.4	8
17	COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. <i>European Journal of Cancer</i> , 2021 , 155, 291-293	7.5	8
16	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 563-569.e3	3.3	7
15	The association between facility case volume and overall survival in patients with metastatic renal cell carcinoma in the targeted therapy era. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018 , 36, 470.e19-470.e29	2.8	4
14	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015 , 14, 511-6	2.4	4
13	The association between race and venous thromboembolism risk after initiation of chemotherapy: An analysis of the SAVE-ONCO trial control arm. <i>American Journal of Hematology</i> , 2017 , 92, E101-E103	7.1	3
12	Can pelvic lymph node dissection be omitted in intermediate-risk prostate cancer patients? A SEER-based comparative study using inverse-probability-of-treatment weighting.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 95-95	2.2	2
11	Racial differences in suicide deaths after cancer diagnosis: A SEER-based analysis of 2,336,949 patients.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 244-244	2.2	1
10	Prevalence of Venous Thromboembolism Diagnosed in Emergency Department Visits by Cancer Patients and Associated Healthcare Resource Utilization in the United States. <i>American Journal of Hematology</i> , 2018 , 93, E207	7.1	1
9	Implications of the United States Preventive Services Task Force Recommendations on Prostate Cancer Stage Migration. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, e12-e16	3.3	0
8	Incidence and predictors of upgrading and upstaging among 10,000 contemporary patients with low-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 32-32	2.2	
7	Incidence and predictors of prostate cancer death in men with other prior malignancies: An analysis from SEER Database.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 34-34	2.2	
6	Determinants for no definitive therapy for early-stage non-small cell lung cancer in U.S. population.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 1590-1590	2.2	
5	Contemporary use of lymph node dissection at nephroureterectomy in treating upper tract urothelial carcinoma: A US population-based analysis.. <i>Journal of Clinical Oncology</i> , 2015 , 33, e15634-e15634	2.2	
4	Variation in national use of long-term ADT by disease aggressiveness among men with unfavorable-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 54-54	2.2	
3	Socioeconomic disparities in the receipt of radiation for node-positive prostate cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 53-53	2.2	

2 Trends and clinico-sociodemographic determinants of stereotactic body radiotherapy use for localized prostate cancer: A National Cancer Database study.. *Journal of Clinical Oncology*, **2017**, 35, e545-545

1 Racial disparities in prostate cancer outcome among prostate-specific antigen screening eligible populations in the United States.. *Journal of Clinical Oncology*, **2017**, 35, 18-18

2.2